Biotech entity
Weiss Ratings is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The 5 average consequence score is below the beat benchmark of 5.2 in the same window. Each story carries 2 original sources on average, compared with 2.1 for the broader beat in this window.
Last mentioned: Aug 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Weiss Ratings is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The 5 average consequence score is below the beat benchmark of 5.2 in the same window. Each story carries 2 original sources on average, compared with 2.1 for the broader beat in this window. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. This profile follows 2 Biotech stories mentioning Maxim Group across the period from August 12, 2026 to August 16, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 29 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Maxim Group. Shared-story counts are live from our verified record — not editorial picks.
Silexion reports quarterly results
Silexion reported a $5.17 loss per share, beating consensus estimates by $16.03; shares fell to $0.42.
Maxim Group downgrades to Hold
Maxim Group lowered Silexion Therapeutics from a Strong-Buy rating to a Hold rating.
Weiss Ratings reiterates Sell (E+)
Weiss Ratings reiterated a Sell (E+) rating on Silexion Therapeutics shares.
Silexion reported a narrower-than-expected loss of $5.17 per share, but analysts downgraded the stock to Hold. Its RNAi LODER candidates remain preclinical or Phase I, and a $0.42 share price may constrain funding for further oncology development.
Source: tickerreport.com · dailypolitical.com
A corporate insider at microcap HCW Biologics disclosed a $19,958.88 purchase of 7,736 shares at $2.58, but conflicting syndicated reports name different insiders. For biotech investors, the transaction highlights a high-risk stock trading 93% below its 52-week high despite a May EPS beat and a $30 Maxim target.
Source: themarketsdaily.com · dailypolitical.com
Maxim Group is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
